Cell Reports

SDHB knockout and succinate accumulation are insufficient for tumorigenesis but dual SDHB/NF1 loss yields SDHx-like pheochromocytomas

Graphical abstract

Authors
Neali Armstrong, Claire M. Storey, Sarah E. Noll, ..., Richard N. Zare, Julien Sage, Justin P. Annes

Correspondence
jannes@stanford.edu

In brief
SDHB knockout in mouse chromaffin cells is not tumorigenic despite ample succinate accumulation and conveyance of cardinal features of SDHB-deficient pheochromocytomas. Armstrong et al. find that dual knockout of SDHB and NF1 yields SDHB-like tumors with accumulation of succinate and H3K9me3, in addition to swollen mitochondria and loss of 5hmC.

Highlights
- Generation and phenotypic characterization of chromaffin cell SDHB knockout mice
- SDHB loss and succinate accumulation are insufficient for pheochromocytoma initiation
- Dual SDHB/NF1 chromaffin cell knockout mice develop SDHx-like pheochromocytomas
- Robust survival of SDHB-deficient chromaffin cells requires an ample redox environment

Armstrong et al., 2022, Cell Reports 38, 110453
March 1, 2022 © 2022 The Authors.
https://doi.org/10.1016/j.celrep.2022.110453
SDHB knockout and succinate accumulation are insufficient for tumorigenesis but dual SDHB/NF1 loss yields SDHx-like pheochromocytomas

Neali Armstrong, Claire M. Storey, Sarah E. Noll, Katherine Margulis, Myat Han Soe, Haixia Xu, Benjamin Yeh, Lauren Fishbein, Electron Kebebew, Brooke E. Howitt, Richard N. Zare, Julien Sage, and Justin P. Annes

1Department of Medicine, Division of Endocrinology, Stanford University, Stanford, CA, USA
2Department of Chemistry, Stanford University, Stanford, CA, USA
3Stanford University, Stanford, CA, USA
4Department of Medicine, Division of Endocrinology, Metabolism, and Diabetes, Division of Biomedical Informatics and Personalized Medicine, University of Colorado School of Medicine, Aurora, CO, USA
5Department of Surgery and Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA
6Department of Pathology, Stanford School of Medicine, Stanford, CA, USA
7Department of Pediatrics and Genetics, Stanford University, Stanford, CA, USA
8Endocrine Oncology Program, Stanford University, Stanford, CA, USA
9Chemistry, Engineering, and Medicine for Human Health (ChEM-H) Institute, Stanford University, Stanford, CA, USA

10Lead contact

*Correspondence: jannes@stanford.edu;
https://doi.org/10.1016/j.celrep.2022.110453

SUMMARY

Inherited pathogenic succinate dehydrogenase (SDHx) gene mutations cause the hereditary pheochromocytoma and paraganglioma tumor syndrome. Syndromic tumors exhibit elevated succinate, an oncometabolite that is proposed to drive tumorigenesis via DNA and histone hypermethylation, mitochondrial expansion, and pseudohypoxia-related gene expression. To interrogate this prevailing model, we disrupt mouse adrenal medulla SDHB expression, which recapitulates several key molecular features of human SDHx tumors, including succinate accumulation but not ShhC loss, HIF accumulation, or tumorigenesis. By contrast, concomitant SDHB and the neurofibromin 1 tumor suppressor disruption yields SDHx-like pheochromocytomas. Unexpectedly, in vivo depletion of the 2-oxoglutarate (2-OG) dioxygenase cofactor ascorbate reduces SDHx-deficient cell survival, indicating that SDHx loss may be better tolerated by tissues with high antioxidant capacity. Contrary to the prevailing oncometabolite model, succinate accumulation and 2-OG-dependent dioxygenase inhibition are insufficient for mouse pheochromocytoma tumorigenesis, which requires additional growth-regulatory pathway activation.

INTRODUCTION

Succinate belongs to a family of so-called “oncometabolites,” a collection of TCA cycle-derived cellular metabolites that can pathologically accumulate to promote cellular metabolic reprogramming and drive neoplasia (Dang et al., 2005; Yang et al., 2013). Normally, succinate is oxidized to fumarate by the mitochondrial enzyme succinate dehydrogenase (SDH), complex II of the electron transport chain and a component of the TCA cycle. Germline loss-of-function mutations in succinate dehydrogenase (SDH) genes (SDHA, SDHB, SDHC, SDHD, or SDHAF2) cause the autosomal dominant hereditary pheochromocytoma and paraganglioma tumor syndrome (hPGL) (Bayliss et al., 2005). The hPGL syndrome exhibits incomplete penetrance, as stochastic loss of the wild-type allele, generally in the context of a partial chromosomal deletion, is required for tumor formation (Fishbein et al., 2017). Tumors with SDHx mutations exhibit impaired succinate-to-fumarate oxidase activity (Rapizzii et al., 2012; Favier et al., 2009) and accumulate succinate to levels as high as 100-fold normal (Lendvai et al., 2014). The current model of SDHx tumorigenesis proposes that high levels of succinate inhibit 2-oxoglutarate (2-OG)-dependent enzymes, leading to epigenetic changes and pseudohypoxia that promote tumorigenesis. Whether succinate accumulation is sufficient to promote tumor formation and how the loss of SDH enzymatic activity leads to tumorigenesis remains uncertain. It is well demonstrated that succinate levels in SDHx-PGCL tumor tissue are substantially elevated relative to non-SDHx tumors and normal organ levels (Lussey-Lepoutre et al., 2016; Richter et al., 2014). In vitro data show that knockdown of SDHx subunits or chemical inhibition of SDH leads to succinate accumulation in diverse cell lines, although the extent of succinate elevation varies substantially (Xiao et al., 2012; Letouze et al., 2013). Consequently, the prevailing hypothesis, based on analysis of
SDHx and other mitochondrial protein mutation–caused tumors (sucinate dehydrogenase [IDH]1/2- and fumarate hydratase [FH]-related glioblastoma and renal cell carcinoma, respectively), is that succinate accumulation acts as an “oncometabo-lite” by competitively inhibiting 2-OG-dependent enzymes, which leads to DNA and histone hypermethylation, and hypoxia-inducible factor (HIF) stabilization. The importance of these pathways in PPGGL tumorigenesis is also supported by the overlapping phenotype caused by mutation of other enzymes in these pathways: VHL, DNA methyltransferase-3ζ (DNMT3A), and HIF2α, which similarly augment HIF and DNA methylation (Hamashita et al., 2016; Fischbein et al., 2017).

The 2-OG-dependent dioxygenase enzymes include the PHD, TET, and KDM/JMJ families (Losman et al., 2020). These enzymes, which modify the epigenetic landscape (TETs and KDM/JMJs) and regulate the adaptive cellular response to hypoxia via HIF1α stability (PHDs), utilize Fe2+, O2, and ascorbate as co-factors and hydroxylate or demethylate their substrates via concomitant oxidation of 2-OG to succinate. The TET enzyme family (TET1, TET2, TET3) are DNA demethylases that mediate the conversion of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC). TET inhibition by succinate manifests historically in SDHx tumors as a loss of Smch immunostaining (Hoekstra et al., 2015a), while epigenetic DNA analysis reveals a substantial increase in CpG Island methylation (Leotouze et al., 2013). The JM/C-domain enzyme family are histone demetylases that mediate the removal of histone lysine methyl groups (Jaukka et al., 2018). These post-translational modifications influence chromatin structure, gene expression, and DNA replication/repair. Succinate inhibition of JM/C enzymes leads to an increase in multiple histone lysine methyl marks, such as H3K9me3, H3K27me3, and H3K4me3 (Leotouze et al., 2013; Hoekstra et al., 2015a).

While there are conflicting data with respect to HIF activation in PPGGLs, it is clear that SDHx tumors exhibit a pseudohypoxic transcriptional signature, which is suggestive of HIF1α activation but does not exclude alternative mechanisms. Indeed, transcriptional analysis of PPGGLs may be used to group tumors into two predominant clusters, reflecting the underlying driver mutation. Cluster 1 tumors, which includes several tricarboxylic acid cycle enzyme genes (SDHx, IDH1/2, FH, and MDH2), have a higher degree of DNA methylation (Fishbein et al., 2017; Daha et al., 2005). Although the transcriptional data is suggestive, methylation differences are significant in human pheochromocytomas does not distinguish between SDHx-mutated and wild-type (wt)-SDHx tumors (Paxer et al., 2005; Castelins et al., 2019) and HIF2α immunostaining is not universally positive in SDHx pheochromocytomas (Poland et al., 2006). The role of succinate inhibition of PHDs and its relationship to the pseudohypoxic transcriptional profile remains incompletely understood.

Given the mechanistic uncertainty of SDHx tumorigenesis, numerous efforts to generate mouse models of Cluster 1 PPGGLs have been made; however, these attempts have been unsuccessful, leading some to suggest its impossibility (reviewed in Lepoutre-Lussey et al., 2016; Lussey-Lepoutre et al., 2018). Approaches taken include global and conditional SDHx disruption (Paxer et al., 2005; Daza-Castro et al., 2012), conditional SDHx deletion, and combined dual SDHx/Phen loss with Psa-Cre (Lepoutre-Lussey et al., 2016) as well as SDHx/p53 loss with Th-Cre (Al Khazal et al., 2022). All of these attempts failed to demonstrate elevated succinate in viable SDHx-deficient tumor cells. Despite this history, we endeavored to address the question of whether the oncometabolite succinate is sufficient to initiate tumorigenesis via 2-OG enzyme inhibition by conditionally disrupting SDHx expression in the mouse chromaffin cells and studying the metabolic, ultrastructural, and transcriptomic consequences.

RESULTS

Loss of SDH in mouse chromaffin cells is neither lethal nor proliferative

To conditionally disrupt SDH in the mouse adrenal medulla, we used mice with LoxP sites flanking exon 3 and bred them to animals expressing Cre recombinase driven by the tyrosine hydroxylase promoter (Th-Cre) (Savitt et al., 2003). We bred Th-Cre SDHβ1/1 animals to the mT/mG Cre-reporter mice (Muzumdar et al., 2007) to rigorously follow the recombined cell population. As previously reported (Savitt et al., 2009), complete Th-Cre-driven recombination occurred in adrenal gland chromaffin cells. To determine the impact of SDH loss on chromaffin cell survival, we compared the percentage of GFP+ medulla areas between SDHβ1/+Rosam/+/Th-Cre (HET) and SDHβ1/+Rosam/+/Th-Cre (SDHβ1/) in adult (8-month-old) animals (Figure 1A). Males from both genotypes had 60% GFP+ medulla area (Figure 1C). Loss of SDH expression was verified by performing western blots on surgically isolated adrenal medullas (Figure 1B). As predicted from incomplete recombination, modest residual SDHβ1 expression was present in SDHβ1/− medulla. Notably, Ki-67 immunostaining was not significantly different between HET and SDHβ1− medullas (Figure 1D). Therefore, in contrast to expectations and prior mouse modeling attempts, SDHβ1 loss neither provoked nor inhibited chromaffin cell proliferation.

To determine if loss of SDH resulted in succinate accumulation, we measured succinate in the adrenal medulla by desorption electrospray ionization-mass spectrometry imaging (DESI-MSI) (Figure 1B). DESI-MSI is a nondestructive ambient ionization method that preserves tissue metabolite distribution, enables detection of minute metabolite alterations, and discriminates between the cortex and medulla of the small murine adrenal gland (Gow et al., 2016; Wiseman et al., 2004; Vijayakumar et al., 2004). Because whole-gland metabolomics data shows an averaged chemical footprint across the cortex and medulla, DESI-MSI was crucial to spatially resolve the distributions of succinate and other metabolite levels between these two adrenal compartments. Indeed, succinate was selectively increased (7.8-fold by averaged abundance) in the medulla of SDHβ1− adrenals compared with controls (Figure 1F). Given that each DESI-MSI pixel (~120 μm2) included 60–100 cells, and approximately 60% of those cells were Cre-recombined, the
actual succinate accumulation per SDHB−/− cell was likely higher. The DESI-MSI spectra also contained peaks for epinephrine and norepinephrine, however, these metabolites were unchanged (Figure 1F). These data provided definitive evidence that mouse SDHB-deficient chromaffin cells were viable and exhibited substantial succinate accumulation.

Having verified that SDHB loss in mouse chromaffin cells was viable and led to succinate accumulation, we analyzed the effects of SDHB loss at an ultrastructural and an immunohistochemical level. Transmission electron micrographs (TEM) of SDHB medulla revealed large clusters of swollen mitochondria in a subset of chromaffin cells (Figures 2A and S1A). Importantly, these clusters were never observed in HET adrenals. This mitochondrial phenotype occurred in SDHB-null cells but not adjacent SDHB-intact cells, reflecting incomplete Tk-Cre-mediated recombination (Figure S1A). Notably, similar mitochondrial ultrastructural changes are characteristically observed in SDHx tumors (Douwes Dekker et al., 2003; Szarek et al., 2015). The TEM findings led us to predict that the mitochondrial clusters represented a general increase in mitochondrial protein that could be used as an immunohistochemical marker for SDHB deficiency. Direct staining for SDHB protein was inconsistent, given a low basal expression level in normal mouse chromaffin cells, where cortical SDHB expression is easily visualized (Figure S1B). Immunostaining of HET and SDHB adrenal glands for several mitochondrial proteins, including cytochrome c and TFAM, demonstrated robust induction in GFP+ cells of SDHB medulla, but not the HET medulla (Figures 2B and S1C). Hence, SDHB disruption caused mitochondrial swelling, clustering, and an apparently expanded mass that was associated with increased mitochondrial protein expression, including the master mitochondrial mass regulator TFAM.

To address the question of whether succinate accumulation in SDHB animals resulted in inhibition of TET, PHD, and KDM enzymes yielding the predicted changes in histone and DNA methylation as well as HIF protein stabilization, we performed a series of co-staining experiments. We co-stained GFP with H3K9me3, ShmC, and HIF1α and compared the staining intensity of each marker between the GFP+ and GFP− populations within a section (Figures 2C, S1D, and S1E). We also looked for HIF2α
but failed to detect nuclear HIF2α in any sample. As shown in Figure 2C, H3K9me3 immunostaining was specifically increased in GFP+ cells from SDHB animals but not HET animals, consistent with succinate-mediated inhibition of a KDM4 enzyme. 5hmC staining of HET controls revealed substantial variability in staining intensity throughout the medulla, with some cell clusters staining intensely and others weakly (Figure S1D). Calculation of the ratio of the 5hmC intensity in GFP+/GFP− medulla populations did not indicate a loss of 5hmC in GFP+ SDHB cells. This result was consistent with the observations that robust changes in 5hmC required cellular division (Lu et al., 2012), a phenotype not substantiated by Ki-67 staining (Figure 1D). Surprisingly, we found substantial HIF1α expression in a subset of normal chromaffin cells and a paradoxical loss of HIF1α expression in the GFP− SDHB population (Figure S1E).

Concomitant loss of SDHB and NF1 induces chromaffin cell proliferation
Aged (>12 months) SDHB animals failed to develop tumors despite succinate accumulation. Therefore, we sought to promote SDHB cell proliferation by providing an additional driving force. While several Cluster 2 genes, such as neurofibromin 1 (NF1) and RET, have been modeled in mice, modeling of Cluster 1 gene (SDHx, VHL, EPAS1)-related PPGLs has been
Figure 3. Simultaneous knockout of NF1 forced proliferation of SDHB chromaffin cells
(A) Representative mTmG fluorescence images of the indicated genotype for male animals at 8 and 22 weeks of age.
(B) Plot of percentage of the medulla area that is GFP+ for each genotype at 8 and 22 weeks (n = 3-4 mice per genotype).
(C) Plot of the increased %GFP+ area between 8 and 22 weeks.
(D) Quantification of Ki67+ medulla nuclei per medulla area for the indicated genotypes. Data are presented as mean ± SD and analyzed using one-way ANOVA and Tukey’s multiple comparison test (n = 4-6 mice per genotype). ***p < 0.001, ****p < 0.0001.

unsuccessful. Accordingly, we asked whether combining Cluster 1 and Cluster 2 gene disruption would enable development of SDHx-like pheochromocytomas. Toward this end, we evaluated publicly available TCGA transcriptomic data from five SDHx and six NF1 (germline mutation) human pheochromocytomas (Fishbein et al., 2017). Interestingly, two of the six germline NF1 pheochromocytomas were transcriptionally classified as Cluster 1 (pseudohypoparathyroidism), illustrating phenotypic overlap between some NF1 and SDHx pheochromocytomas. Additionally, loss of the NF1 locus (17q11) has been observed in some SDHB PPGLs (Fishbein et al., 2017). These data, combined with the knowledge that SDHB and NF1 tumors both exhibit loss of the 1p chromo-
some, suggested possible overlapping tumorigenic mechanisms. On the basis of apparently overlapping mechanisms of NF1 and SDHx pheochromocytoma formation, we tested whether combined NF1 and SDHB disruption could drive SDHx-like pheochromocytoma formation in mice.

NF1 is a GTPase-activating protein that negatively regulates the RAS/MAPK and PI3K/mTOR pathways (Klur and Busam, 2017). In prior work, approximately 18% of mice heterozygous for a NF1 loss-of-function mutation developed pheochromocytomas (Jack et al., 1999). We reasoned that if the SDHB mice failed to develop pheochromocytomas as a consequence of a missing replication trigger, simultaneous loss of NF1 would be sufficient to induce tumor formation. Toward this end, we bred SDHB01 and NF1/1 animals (Zhu et al., 2001) to generate the following experimental genotypes: SDHB-NF1/Rosamtm4/Th-Cre (HET/HET), SDHB-NF1/Rosamtm4/Th-Cre (SDHB/HET), SDHB-NF1/Rosamtm4/Th-Cre (HET/ NF1), and SDHB-NF1/Rosamtm4/Th-Cre (SDHb/NF1).

When adrenal medullas from all four genotypes were examined at 8 weeks of age, both SDHB/NF1 (25.5%) and HET/NF1 (34.1%) glands had significantly more GFP+ area compared with SDHB/HET glands (22%) (Figures 3A–3C). The difference between HET/HET and SDHB/HET %GFP+ area at 8 weeks was not statistically different. When animals were aged to 22 weeks, differences were more prominent. At 22 weeks, 71% of the SDHB/NF1 medulla area was GFP+ compared with 53% in HET/HET and 60% in HET/NF1 medullas. Notably, the patterns of SDHB/NF1 and HET/NF1 GFP+ cell expansion...
Figure 4. SDHB/NF1 chromaffin cells displayed swollen mitochondria, excess succinate, and hypermethylation.

(A) Representative TEM images of chromaffin cell mitochondria for each genotype imaged at 120,000× magnification. Scale bar, 1,000 nm. (B) Representative DESI-MSI images of succinate for 3 samples from each genotype. Scale bar is percentage of total ion current. (continued on next page)
were distinct. In the SDHB/NF1 medullas, GFP+ cell clusters were uniformly distributed; however, GFP+ cell clusters in HET/NF1 medullas were mostly similar to HET/HET medullas with discrete areas of densely packed GFP+ cells, suggestive of nodular hyperplasia (Figure 3A). Importantly, SDHB/NF1 medulla exhibited the highest replication activity (Ki-67+ nuclei; Figure 3D), demonstrating a cooperative proliferative effect of concurrent SDHB and NF1 gene disruption. The increased SDHB/NF1 medulla replication (Ki-67) and expanded GFP+ area led to increased adrenal gland mass. Both SDHB/NF1 and HET/NF1 glands were approximately 24% heavier than control glands (Figure S2A) at 22 weeks. Paradoxically, SDHB/HET glands were 47% larger than those of controls; however, this was related to increased cortical area and fat accumulation (see below).

SDHB/NF1 adrenal glands accumulated succinate and were hypermetabolic

Next, we investigated whether SDHB/NF1 medullary cells, like their SDHB counterpart, exhibited succinate accumulation and the striking mitochondrial phenotype. Indeed, TEM ultrastructure analysis revealed that HET/NF1 mitochondria were indistinguishable from Cre negative controls, whereas SDHB/NF1 cells contained large clusters of swollen mitochondria with remarkably intact cristae, as observed in SDHB/HET medullas (Figure 4A). DESI-MSI analysis of HET/NF1 and SDHB/NF1 adrenal sections confirmed elevated succinate abundance in the SDHB/NF1 but not HET/NF1 medullas, which were indistinguishable from those of controls (Figures 4B and 4C). Catecholamine levels in these 5-month-old animals were not significantly changed from those of controls (Figure 5A). These data indicated a dominant effect of the SDHB-associated phenotype in the context of concurrent NF1 deficiency.

Next, we explored whether the hypermetabolism phenotype of replicating SDHB/NF1 cells was distinct from SDHB chromaffin cells. In contrast to SDHB/HET adrenal glands, HET/NF1 and SDHB/NF1 samples demonstrated significantly reduced 18F MIBG staining intensity in GFP+ nuclei relative to the GFP- nuclei (Figures 4D and 4E). However, at that age, loss of 18F MIBG in HET/NF1 (30%) and SDHB/NF1 (42%) was not statistically different. Notably, as observed in the SDHB medullas, H3K27me3 levels were elevated in the SDHB/NF1 GFP+ cell population but unchanged in HET/NF1 medullas (Figures 4D and 4F). Thus, loss of NF1 is sufficient to reduce 18F MIBG but does not promote histone hypermethylation, which selectively occurs in SDHB-deficient medullas.

**Aged SDHB/NF1 animals developed medullary hyperplasia and pheochromocytomas**

To ascertain whether the increased Ki-67, GFP+ cell expansion and adrenal weights observed in the 22-week-old SDHB/NF1 animals were indicative of early stages of tumor formation, we aged (12–20 months) more than 100 genotypically diverse (No Cre, HET/HET, HET/NF1, SDHB/HET, and SDHB/NF1) animals. Aged (12–18 months) HET/NF1 animals exhibited decreased body weight (averaging 13.8 g), whereas SDHB/HET animals developed obesity (averaging 17.5 g) (Figure S3A). Notably, obese SDHB/HET animals did not develop diabetes, apparently because of compensatory islet mass expansion and increased insulin secretion capacity (Figure S3B–S3F). This non-diabetic obese phenotype was similarly observed in SDHC-deficient mice (Al Khazal et al., 2020) and was attributed to a loss of hypothalamic neurons.

The adrenal gland mass of SDHB/NF1 animals increased significantly in aged mice (Figure 5A). We defined a tumor as an adrenal gland over 6 mg. Using this cutoff, we found tumors in 76% of SDHB/NF1 and in 53% of HET/NF1 adrenal glands (Figures 5A and 5B). Among animals with tumors, 58% of SDHB/NF1 animals had bilateral tumors compared with only 25% of HET/NF1 animals, indicating higher pheochromocytoma penetrance in the double-knockout mice compared with HET/NF1 mice. There was no significant difference in the average weight of SDHB/NF1 and HET/NF1 tumors. Histologic analysis confirmed tumors to be pheochromocytoma (Figures 5C and 5A) with solid growth, usually as organoid clusters of epithelioid to polygonal cells with abundant eosinophilic to amphiphilic granular cytoplasm and round nuclei with smooth contours. Occasional tumors demonstrated increased nuclear atypia and ganglion-like cell morphology, which are uncommon in human pheochromocytoma. Notably, we found one tumor among SDHB/HET adrenal glands and two among HET/HET adrenal glands; potentially related to prior work reporting pheochromocytoma formation in heterozygous NF1 mice (Jacks et al., 1995). We did not observe metastases in the liver or lungs, although an exhaustive search for micro-metastases was not performed. We conclude that SDHB/NF1 disruption in mouse adrenal medulla was tumorigenic and that NF1-driven tumorogenesis was enhanced by loss of SDHB.

Next, we evaluated the molecular differences between HET/NF1 and SDHB/NF1 tumors. We compared succinate levels in the adrenal glands of controls, HET/NF1 tumors, and SDHB/NF1 tumors by DESI-MSI. Indeed, SDHB/NF1 tumors exhibited an average 

**Cell Reports**

**Article**

**OPEN ACCESS**

were distinct. In the SDHB/NF1 medullas, GFP+ cell clusters were uniformly distributed; however, GFP+ cell clusters in HET/NF1 medullas were mostly similar to HET/HET medullas with discrete areas of densely packed GFP+ cells, suggestive of nodular hyperplasia (Figure 3A). Importantly, SDHB/NF1 medulla exhibited the highest replication activity (Ki-67+ nuclei; Figure 3D), demonstrating a cooperative proliferative effect of concurrent SDHB and NF1 gene disruption. The increased SDHB/NF1 medulla replication (Ki-67) and expanded GFP+ area led to increased adrenal gland mass. Both SDHB/NF1 and HET/NF1 glands were approximately 24% heavier than control glands (Figure S2A) at 22 weeks. Paradoxically, SDHB/HET glands were 47% larger than those of controls; however, this was related to increased cortical area and fat accumulation (see below).

SDHB/NF1 adrenal glands accumulated succinate and were hypermetabolic

Next, we investigated whether SDHB/NF1 medullary cells, like their SDHB counterpart, exhibited succinate accumulation and the striking mitochondrial phenotype. Indeed, TEM ultrastructure analysis revealed that HET/NF1 mitochondria were indistinguishable from Cre negative controls, whereas SDHB/NF1 cells contained large clusters of swollen mitochondria with remarkably intact cristae, as observed in SDHB/HET medullas (Figure 4A). DESI-MSI analysis of HET/NF1 and SDHB/NF1 adrenal sections confirmed elevated succinate abundance in the SDHB/NF1 but not HET/NF1 medullas, which were indistinguishable from those of controls (Figures 4B and 4C). Catecholamine levels in these 5-month-old animals were not significantly changed from those of controls (Figure 5A). These data indicated a dominant effect of the SDHB-associated phenotype in the context of concurrent NF1 deficiency.

Next, we explored whether the hypermetabolism phenotype of replicating SDHB/NF1 cells was distinct from SDHB chromaffin cells. In contrast to SDHB/HET adrenal glands, HET/NF1 and SDHB/NF1 samples demonstrated significantly reduced 18F MIBG staining intensity in GFP+ nuclei relative to the GFP- nuclei (Figures 4D and 4E). However, at that age, loss of 18F MIBG in HET/NF1 (30%) and SDHB/NF1 (42%) was not statistically different. Notably, as observed in the SDHB medullas, H3K27me3 levels were elevated in the SDHB/NF1 GFP+ cell population but unchanged in HET/NF1 medullas (Figures 4D and 4F). Thus, loss of NF1 is sufficient to reduce 18F MIBG but does not promote histone hypermethylation, which selectively occurs in SDHB-deficient medullas.

**Aged SDHB/NF1 animals developed medullary hyperplasia and pheochromocytomas**

To ascertain whether the increased Ki-67, GFP+ cell expansion and adrenal weights observed in the 22-week-old SDHB/NF1 animals were indicative of early stages of tumor formation, we aged (12–20 months) more than 100 genotypically diverse (No Cre, HET/HET, HET/NF1, SDHB/HET, and SDHB/NF1) animals. Aged (12–18 months) HET/NF1 animals exhibited decreased body weight (averaging 13.8 g), whereas SDHB/HET animals developed obesity (averaging 17.5 g) (Figure S3A). Notably, obese SDHB/HET animals did not develop diabetes, apparently because of compensatory islet mass expansion and increased insulin secretion capacity (Figure S3B–S3F). This non-diabetic obese phenotype was similarly observed in SDHC-deficient mice (Al Khazal et al., 2020) and was attributed to a loss of hypothalamic neurons.

The adrenal gland mass of SDHB/NF1 animals increased significantly in aged mice (Figure 5A). We defined a tumor as an adrenal gland over 6 mg. Using this cutoff, we found tumors in 76% of SDHB/NF1 and in 53% of HET/NF1 adrenal glands (Figures 5A and 5B). Among animals with tumors, 58% of SDHB/NF1 animals had bilateral tumors compared with only 25% of HET/NF1 animals, indicating higher pheochromocytoma penetrance in the double-knockout mice compared with HET/NF1 mice. There was no significant difference in the average weight of SDHB/NF1 and HET/NF1 tumors. Histologic analysis confirmed tumors to be pheochromocytoma (Figures 5C and 5A) with solid growth, usually as organoid clusters of epithelioid to polygonal cells with abundant eosinophilic to amphiphilic granular cytoplasm and round nuclei with smooth contours. Occasional tumors demonstrated increased nuclear atypia and ganglion-like cell morphology, which are uncommon in human pheochromocytoma. Notably, we found one tumor among SDHB/HET adrenal glands and two among HET/HET adrenal glands; potentially related to prior work reporting pheochromocytoma formation in heterozygous NF1 mice (Jacks et al., 1995). We did not observe metastases in the liver or lungs, although an exhaustive search for micro-metastases was not performed. We conclude that SDHB/NF1 disruption in mouse adrenal medulla was tumorigenic and that NF1-driven tumorogenesis was enhanced by loss of SDHB.

Next, we evaluated the molecular differences between HET/NF1 and SDHB/NF1 tumors. We compared succinate levels in the adrenal glands of controls, HET/NF1 tumors, and SDHB/NF1 tumors by DESI-MSI. Indeed, SDHB/NF1 tumors exhibited an average 28-fold increase in medullary succinate relative to aged control adrenal glands (Figures 5D and 5E). None of the HET/NF1 tumors had elevated succinate. For comparison, we also measured succinate abundance in three human SDHx PGLs, two apparently sporadic PGLs, and one normal adrenal gland (Figure 5F and Table S1). In the three human SDHx PGLs, tissue-averaged succinate abundances were 33- to 137-fold higher relative to the normal adrenal. Interestingly, PGL-6 came from a young woman diagnosed with Carney Triad (CT) on the basis of multiple PGLs, wild-type GSTT, and negative SDHx germline testing. This tumor exhibited equivocal SDHB staining, strong cytochrome c staining, and a 75-fold increase in 18F MIBG uptake.
Figure S5. Pheochromocytoma development in 13-month-old SDHB/NF1 mice
(A) Log y plot of adrenal weight by animal genotype for animals aged over 1 year. The dashed line marks the 6-mg cutoff for tumors.
(B) Table of tumor findings from the aged cohort.
(C) H&E staining of representative adrenals from each genotype. Normal adrenal glands (HET/HET) contain a small amount of central medullary adrenal tissue surrounded by the adrenal cortex, which is non-compressed. In SDHB/HET adrenal glands, there was slight enlargement of the gland but no tumor formation. In contrast, the adrenal glands from HET/NF1 and SDHB/NF1 mice have expansive growth of the adrenal medulla, consistent with pheochromocytoma, resulting in compression of the surrounding adrenal cortex.
(D) DESeq-MS images of succinate (m/z = 117.0119) and PCC-17 (m/z = 86.5448) in human PPGLs and non-adrenal.

(legend continued on next page)
in succinate abundance. These findings highlighted the utility of DESI-MSI for identifying somatic SDHx-related tumors; indicating fallibility of SDHB immunohistochemistry, anticipated to be lost in CT as a result of epigenetic SDHC silencing, or the existence of an undescribed succinate-associated tumorogenic mechanism with retained SDHB expression.

Immunohistochemical analysis revealed that SDHB/NI1 tumors had virtually complete loss of ShhC, which was retained by intervening sustentacular cells and occasional unrecombined (GFP-) chromaffin cells (Figure 5G). In contrast, HET/NI1 tumors exhibited weak, but persistent, ShhC immunostaining. Although H3K9me3 staining was detected in both SDHB/NI1 and HET/NI1 tumors, it was more intense throughout double-knockout tumors (Figure 5G). Interestingly, 12-month-old SDHB mice, which did not have an expanded GFP+ cell population, had the same methylation pattern observed in 6-month-old SDHB animals (H3K9me3 induction without loss of ShhC). These data again indicated that histone hypermethylation was insufficient for tumor initiation and that prolonged exposure to elevated succinate was not sufficient to cause loss of ShhC. Perhaps the most striking difference between the SDHB/NI1 and HET/NI1 tumors was the induction of cytochrome c (Figure 5G). These data raised the possibility of leveraging cytochrome c staining as a surrogate marker for human SDHx tumors.

To ascertain how similar the characteristics of the SDHB/NI1 mouse tumors were to human SDHx tumors and if cytochrome c could reliably distinguish between SDHx and non-SDHx tumors, we applied the cytochrome c/H3K9me3/ShhC staining protocol to a panel of 30 genetically characterized human PPGLs (Table S2). As shown in Figure 5G, the human SDHx tumor cells stained robustly for cytochrome c and at the same time had almost complete loss of ShhC immunostaining while inducing H3K9me3 in the cytochrome c-positive population. Intervening sustenacular cells were intensely ShhC positive and only weakly stained for H3K9me3 and cytochrome c. The 15 non-Cluster 1 PPGLs had only background cytochrome c staining and weakly diffuse H3K9me3 and ShhC. Indeed, Cluster 1 PPGLs (13 SDHx and 2 VHL) could be distinguished from non-Cluster 1 tumors on the basis of cytochrome c staining intensity (Figure S4B) indicating that cytochrome c staining intensity may be used to identify SDHx and, possibly, VHL PPGLs. Importantly, our mouse SDHB/NI1 tumors displayed a remarkably similar staining pattern to the human SDHx tumors, suggesting that it accurately models these histological aspects of the human disease.

**SDHB/NI1 tumors were enriched in mitochondrial and ribosomal transcripts**

A hallmark and discriminating feature of human pheochromocytoma is their predominant clustering into two groups based on transcriptional signatures. Cluster 1 tumors, including SDHx, VHL, and EPAS1, are characterized by hypoxia-related transcript enrichment. Cluster 2 tumors, including NF1, RET, and HRAS, are defined by enrichment in kinase-signaling pathway transcripts. We sought to determine whether the SDHB/NI1 and HET/NI1 mouse tumors similarly formed transcriptional clusters, what pathways/genes defined these clusters, and how they compared with human transcriptional signatures. We performed RNA-seq of SDHB/NI1 and HET/NI1 tumors, and age-matched normal adrenal medulla (NAM) controls. Principal component analysis revealed three distinct clusters, which were separated according to genotype (Figures 6A and S4C); 3,679 genes were differentially expressed (p < 0.05) between SDHB/NI1 and HET/NI1 tumors. Importantly, the SDHB transcripts were significantly decreased by 57% and 89% in HET/NI1 and SDHB/NI1 tumors relative to NAM, respectively (Figure S4D), confirming the heterozygous and homozygous knockout of SDHB in these tumors.

Next, we performed gene set enrichment analysis of SDHB/NI1 and HET/NI1 tumors relative to NAM to determine which KEGG pathways were enriched. As expected, both SDHB/NI1 and HET/NI1 tumors had significant enrichment within the CELL CYCLE and DNA REPLICATION pathways (Figure 6B). Unexpectedly, the RIBOSOME pathway was the most enriched pathway among SDHB/NI1 tumors but was not enriched in HET/NI1 tumors. Notably, SDHB/NI1 tumors also demonstrated significant alteration of multiple DNA repair pathways, which was substantially less in HET/NI1 tumors. These results were consistent with impaired DNA repair observed in human SDHx tumors (Sukowski et al., 2020; Sukowski et al., 2019). Human PPGLs pathway analysis has generally compared differences between tumor types (Lopez-Jimenez et al., 2013). A similar analysis comparing SDHB/NI1 with HET/NI1 tumors showed that SDHB/NI1 tumors were most enriched in RIBOSOME and OXIDATIVE PHOSPHORYLATION (up-regulated expression), whereas HET/NI1 tumors were most significantly enriched for transcripts in the ECM RECEPTOR INTERACTION, vascular endothelial growth factor (VEGF), NOTCH, and TGF-ß signaling pathways (Figures 6C and 6D). Remarkably, parallel analysis performed with the human SDHx and NF1 germline pheochromocytomas from the TCGA dataset (Fishbein et al., 2017) demonstrated overlapping enrichment in KEGG pathways, including ribosome and oxidative phosphorylation, in Cluster 1 tumors (Figure S4E). These data highlight the robust transcriptional similarity between human SDHx and mouse SDHB/NI1 pheochromocytomas.

Comparison of mouse SDHB/NI1 and human SDHx tumors with HET/NI1 (mouse) and NF1 (human) pheochromocytomas, respectively, demonstrated significant enrichment of oxidative phosphorylation and mitochondrial DNA-encoded transcripts (Figures 6C and 6E). These data, along with the large number of swollen mitochondria observed by EM, indicated a SDHB-associated expansion in mitochondria number. This conclusion was further substantiated by an ~2-fold increase in SDHB/NI1 tumor mitochondrial DNA copy number relative to HET/NI1
Figure 6. Transcriptomics of mouse tumors revealed enrichment of mitochondrial and ribosomal gene transcripts

(A) Heatmap and hierarchical clustering of top 1,200 most significantly up- and down-regulated transcripts between SDHB/NF1 and HET/NF1 tumor groups.
(B) KEGG gene set enrichment for SDHB/NF1 and HET/NF1 tumors relative to normal adrenal medulla. Pathways with p < 0.01 were selected. Pathways with p < 0.05 were enriched in SDHB/NF1 tumors and their relative enrichment in HET/NF1 tumors. Numbers in parentheses are the system identifiers for each KEGG pathway.
(C) KEGG gene set enrichment for SDHB/NF1 tumors relative to HET/NF1 tumors. Pathways with p < 0.05 were selected. Pathways with p < 0.05 were enriched in HET/NF1 tumors. Numbers in parentheses are the system identifiers for each KEGG pathway.

(D) Heatmap showing enrichment of mitochondrial DNA-encoded transcripts in mouse and human tumors. Red stars indicate the two NF1 phaeochromocytomas, which were classified as pseudohypoparathyroidism.

(legend continued on next page)
tumors and NAM (Figure 6F). Consistent with these findings were 9- and 2.4-fold increases in PPARγ2 expression in SDHB/−NF1 and human SDHx pheochromocytomas, respectively (Figure 5G). Notably, the mitochondrial DNA-encoded signature was dissociated from the hypoxia signature in the human samples we analyzed; the two NF1 tumors that contained a pseudohypoxia signature did not contain a mitochondrial DNA gene expression signature (Figure 4E).

Our pathway analysis did not uncover significant enrichment of either hypoxia or HIF-regulated pathways when we compared SDHB/−NF1 with HET/NF1 mouse tumors. By contrast, SDHx human tumors were significantly enriched in Hallmark_Hypoxia transcripts. It was unclear why SDHB/−NF1 tumors lacked a pseudohypoxic signature; however, we suspect that pseudohypoxia may be acquired during later stages of tumor progression, since two of the four SDHB/−NF1 samples exhibited increased expression of some HIF-regulated transcripts such as Ccnd4 and EPA2.

**Ascorbate depletion was lethal to SDHB-null chromaffin cells**

The adrenal gland contains one of the highest deposits of ascorbate in the body, where it is found at millimolar levels in both mice and humans (Kim et al., 2012). Within the adrenal, DESI-MS imaging of ascorbate generally showed higher abundance in the medulla and around the corticomediullary border (Figures 7A and S5). The effect of ascorbate depletion on human SDHx tumors, we demonstrate the utility of DESI-MS for targeted tracking of metabolic changes in the adrenal medulla by spatially resolving the distinct molecular profiles of the cortex and medulla. However, after 1 year of aging, SDHB-deficient chromaffin cells do not exhibit increased proliferation, loss of melanin, HIF1α accumulation, or significant changes in catecholamine abundances. These data definitively show that, in mice, loss of SDHB in chromaffin cells is insufficient for tumorigenesis despite high levels of succinate. There are several unique aspects to SDHx tumor genetics that suggest that loss of an additional tumor suppressor, proposed to be located in SDHx−adjacent regions of the genome, is required for initiation of tumorigenesis. The strongest evidence for this comes from SDH mutations, which primarily promote PPGL formation after paternal inheritance. Since the SDHD locus is not imprinted, the prevailing hypothesis is that loss of an adjacent imprinted gene is required for tumor initiation (Heeksstra et al., 2015b). Indeed, loss of heterozygosity (LOH) for SDHD tumors occurs with loss of the maternal copy of chromosome 11. With respect to SDHB, which is located on 1p36.13, it is important to note that LOH for virtually all SDHB tumors occurs via loss of the 1p chromosome arm (Fischbein et al., 2017), and this has been shown to be an early event in tumor formation (Fischbein et al., 2003; Dancyang et al., 2003). Indeed, those attempting to model IDH1/2 mutations (Sasaki et al., 2012; Philip et al., 2018) and FH knockout (Adam et al., 2011) similarly concluded that loss of additional genes was necessary for tumor initiation. All together, our data, plus those from IDH and FH models, and

---

(1) Quantification of mitochondrial DNA copy number by qPCR analysis (16S rRNA and ND1/microsatellite) from mouse tumors and NAM (p < 4E-6).
(2) Normalized counts of transcripts for PPARγ2 (64950) from mouse and human tumors and mouse NAM. Data are presented as mean ± SD and analyzed using an unpaired t test, *p < 0.01.
Figure 7. Ascorbate levels decreased in mouse and human tumors, but ascorbate depletion was paradoxically lethal to developing SDHB cells.

(A) Representative DESI-MSI images of ascorbate for control, HET/NF1, and SDHB/NF1 glands at 12 months.

(B) DESI-MSI images of ascorbate from normal human adrenal and PPGALs. All images were normalized as %TKC.

(C) Average abundance of ascorbate in the medulla, extracted from DESI-MSI data (n = 4–6 for mouse; n = 1–5 for human).

(D) Representative m/z images of male HET and SDHB adenals in GULOΔΔ and GULOΔ−/Δ− animals.

(E) Quantification of %GFP medulla area for male 10-week-old animals. Data are presented as mean ± SD and analyzed using a one-way ANOVA. **Adjusted-p value < 0.01.

(legend continued on next page)
the underlying genetic events in SDHx tumors, support the hypothesis that oncometabolite accumulation is insufficient for tumor initiation. Hence, we propose copy number loss with LOH (CNL-LOH) as the genetic mechanism of SDHB-dependent tumorigenesis.

In this study, we used loss of NF1 to initiate tumorigenesis in the SDHb mouse model. However, it is important to note that there is no evidence that biallelic NF1 and SDHb mutations co-occur in human PPGLs and that most tumors arise from individuals with germline NF1 or SDHB mutations have many different characteristics (Fishbein et al., 2017). Despite the differences in SDHB and NF1 tumor phenotypes, there is reason to believe there are overlaps in their tumorigenic mechanisms. Indeed, the 1p arm is also lost in most NF1 phaeochromocytomas. Additionally, the two major pathways activated by loss of NF1, the Ras-Raf-Erk and PI3-Akt-mTOR pathways, are also activated in SDHx cells and tumors. For example, phospho-Erk1/2 has also been shown to accumulate in SDHB-null cells (Chen et al., 2014), and many mTORC pathway components are upregulated in SDHx tumors (Ouldjik et al., 2017). Moreover, it has been proposed that germline inheritance of many pheochromocytoma susceptibility genes, such as SDHx and NF1, share a common pathway for inhibition of apoptosis, which culminates in inhibition of PHD3 activity (Lee et al., 2009). Furthermore, a direct effect of NF1 on the SDH complex has been identified (Masgras et al., 2017). It is informative to note that the combined deletion of SDHB and NF1 was successful, whereas many other SDHx plus tumor suppressor gene combinations failed to initiate tumors in mice. For example, the PSA-Cre SDHB/Pten deletion produced tumors without elevated succinate, leading to the conclusion that only Pten-recombined cells survived recombinant. Tumors also did not arise from the combined loss of SDHC with p53 or hypoxia (10% O2) (Alkhazal et al., 2020). Indeed, prior studies have not found loss of p53 in chromaffin cells to be tumorigenic (Tonks et al., 2010) unless combined with loss of PTEN or RB1, suggesting that specific pathways need to be simultaneously targeted to effect proliferation. The ability to convert a Cluster 2 cell type into a Cluster 1 cell type, shown here, suggests that there are overlapping tumorigenic pathways in these clusters and that high succinate levels and subsequent hypermethylation are a main feature driving the phenotypic distinctions between these tumor types.

Hypermethylation is commonly described in human malignancies, and several mechanisms exist by which ShmC levels and TET activity can be modulated (Pfeifer et al., 2014). In the case of SDHx, IDH1/2, and FH tumors, the proposed mechanism is oncometabolite-mediated TET inhibition. However, other mechanisms, such as nuclear exclusion of TET1 enzyme (Muiler et al., 2012), TET silencing via promoter hypermethylation (Li et al., 2016), and increased expression of IDH1 (Chen et al., 2014) have also been described. In our system we find that NF1-null chromaffin cells exhibit a reduction of ShmC in pre-tumor adenals, whereas the SDHB-null cells retain ShmC immunostaining. The NF1 result is consistent with reports showing that almost all PPGLs have loss of ShmC relative to adjacent sustentacular cells, while SDHx tumors have a more extreme shift in this ratio (see Hoeckstra et al., 2015). So, why does elevated succinate appear insufficient for TET inhibition in our SDHB-null cells but sufficient for KDM4 inhibition? The succinate level which inhibits TET1s and KDM4s are fairly similar (Juvvaka et al., 2018), suggesting these enzymes should be equivalently inhibited by succinate. We propose that TET inhibition does occur in SDHB-null cells, but in order to observe a robust change in ShmC marks, multiple rounds of cellular division are required. Evidence of this phenomenon was seen in experiments with IDH1-R132H cells, which gained tri-methyl histone H3 marks within a few passages, but loss of ShmC required at least 12 passages (Ju et al., 2012). Indeed, in SDHB-NF1 tumors there was virtually no detectable ShmC immunostaining, whereas NF1 tumors retained a low level of ShmC, demonstrating that cellular succinate levels were sufficient for TET inhibition but loss of ShmC was manifested only in cycling cells, not arrested cells. This also suggests that DNA hypermethylation per se is unlikely to be a driver of tumorigenesis but rather an effector that exacerbates progression over time. Alternatively, it is possible that the methylation patterns are sufficiently different between mouse and human such that oncometabolite-driven hypermethylation followed by tumor initiation is not possible in mice (in other words, the “right” genes do not get silenced in mice).

A hallmark feature of SDHx tumors is the upregulation of hypoxia-related transcripts. However, SDHB/NF1 tumors do not significantly upregulate Hif1/2α nor hypoxia transcripts. HIF stabilization is also absent from other oncometabolite mouse models. For example, HIF1α accumulation was not observed in IDH1(R132H) knockin mice targeted to the subventricular zone, although hypermethylation was evident (Banerjea et al., 2018). The kidney cysts that resulted from loss of nuclear Hif1-α however dual knockout of FH and HIF1/2α in the kidney did not ameliorate the cystic phenotype; suggesting that HIF was not phenotypically relevant (Adams et al., 2011). Ultimately, these data do not resolve the role of HIF activation in SDHx tumors; however, our data, and those of others, indicate that the proposed mechanisms of succinate-mediated PHD inhibition is incomplete. Additional events such as ROS accumulation (Gonzales et al., 2021) and/or CNL-LOH may be necessary for acquisition of the pseudo-adrenocortical phenotype late in the tumorigenic process.

Finally, in considering why succinate is insufficient to drive tumorigenesis in SDHB mice, we explored the hypothesis that high ascorbate levels in the adrenal medulla were sufficient to maintain residual dioxygenase enzyme activity and suppress tumor formation. This phenomenon has been observed in
IDH1R132H cell lines where vitamin C treatment increased ShmC marks despite the presence of 2-HG (Mingay et al., 2018). High-dose vitamin C can also overcome the loss of Tet2 in a mouse model for leukemia (Cimmino et al., 2017). Conversely, leukemogenesis is accelerated in ascorbate-depleted Gulo-/- mice transplanted with Fl1TdTET2+/- HSCs (Agathocleous et al., 2017). Given these data, we expected that ascorbate depletion would further inhibit activity of 2-OG enzymes and initiate tumor formation. However, to our surprise, ascorbate depletion in SDHB animals led to a significant and preferential loss of SDHB-deficient cell viability, showing that ascorbate is required for cellular survival after loss of SDH activity and, potentially, indicating why SDHx mutations are associated with PPGLs, cell types with relatively high ascorbate levels. In support of this hypothesis, C. elegans, which lack a gulo gene, exhibit premature aging and early death when their sdh phenotype is knocked-out. Remarkably, this effect was largely reversed by the addition of ascorbate to the growth medium (Huang and Lemire, 2009). Similarly, TH-SDHD mice displayed a preferential loss of substantia nigra dopaminergic neurons, which were partially rescued by the addition of an antioxidant in the drinking water (Jimenez-Castro et al., 2012). The requirement for a plentiful cellular redox environment has also been shown in other models of loss of TCA cycle genes. In FH mouse models, the Nrf2 antioxidant pathway was the most upregulated transcriptional pathway in FH renal cysts (Aden et al., 2011). In contrast to the initial requirement for abundant ascorbate, we measured a significant loss of ascorbate in human PPGLs relative to normal adrenals. We propose that during tumor progression metabolic reprogramming relates the ascorbate-dependence, which in turn potentiates 2-OG enzyme inhibition. Indeed, it has recently been shown that ultra-high-dose ascorbate preferentially kills both SDHB cell lines (Gonzalez et al., 2021) and SDHB allografts (Liu et al., 2020). Notably, the role of ascorbate in maintaining the viability of SDH deficient chromaffin cells does not explain the increased risk of SDHx-associated renal cell carcinoma and gastrointestinal stromal tumor, where ascorbate levels are low and alternative mechanisms of remediating oxidative stress, perhaps via glutathione regulation, would be required.

In summary, loss of SDHB in the mouse adrenal medulla is compatible with cell survival which is enabled by the high levels of ascorbate in the adrenal gland. Chromaffin cells respond to loss of SDHB by accumulating succinate, clustered swollen mitochondria, and histone hypermethylation, but not increased proliferation. Our data strongly substantiate a requirement for a second, unspecified, genetic event in SDHB tumors that is necessary for cell-cycle entry and tumorogenesis. We suspect that, in humans, as in the mouse, an additional gene(s), probably located on the 1p arm, must be concurrently lost to initiate tumor formation. We propose that upon CNL-LOH, succinate accumulates, metabolic adaptation takes place (mitochondrial swelling), and histone methylation is initiated (Figure 7F). This tumor initiation stage includes a heterozygous state for the 1p co-tumor suppressor(s) which are presumed to be haploinsufficient at this stage of tumor initiation. Subsequently, we hypothesize, the remaining wildtype allele(s) are epigenetically silenced through successive rounds of cellular division. The final neoplastic stage is achieved when the remaining 1p tumor suppressor gene(s) are sufficiently silenced. We further hypothesize that neoplasia is enforced by ascorbate loss, which triggers a pseudohypoxic transcriptional phenotype. Our unique success from combining SDHB and NF1, when several other combinations have failed, provides important new insights into the molecular mechanisms of SDHx tumorigenesis and a valuable new resource. Although a variety of cellular in vitro and transplant models exist, these suffer from several fundamental deviations including an uncharacteristically high replication rate. The SDHB/NF1 mouse model of PPGL is a valuable new experimental resource that may be leveraged to better understand SDHx tumorigenesis, uncover new therapeutic avenues, and, perhaps most importantly, establishes the feasibility of modeling SDHB-deficient tumors in mice.

Limitations of the study

A limitation to this study is the use of NF1 disruption as a driving force for SDHB-deficient tumor formation. Homozygous loss of SDHB and NF1 has not been described in the human PPGLs. Another limitation is that complete ascorbate depletion is lethal to Gulo-/- animals by 10 weeks of age. Hence, the tumorogenic potential of surviving SDH-deficient chromaffin cells, in the context of ascorbate depletion, could not be assessed. To study the long-term consequences of ascorbate deprivation on SDHB cellular survival and tumor formation, studies need to be conducted with an ultra-low ascorbate diet for several months. Finally, we have not evaluated the effect of ascorbate on dual NF1- and SDHB-deficient mouse tumors; hence the selective lethality of ascorbate depletion toward mouse SDH-deficient chromaffin cells should not be extrapolated to survival of mouse or human SDH-deficient tumors.

STAR Methods

Detailed methods are provided in the online version of this paper and include the following:

- **Key Resources Table**
- **Resource Availability**
  - Lead contact
  - Materials availability
  - Data and code availability
- **Experimental Models and Subject Details**
  - Mice
  - Human samples for DESI-MSI
  - Human samples for cytochrome C analysis
- **Method Details**
  - mT/mG fluorescence imaging and GFP area quantification
  - Histopathology and immunohistochemistry
  - Human tumor cytochrome C immunostaining and image analysis
  - Western blotting
  - DESI-MSI
  - Identification of ion species by MS/MS
  - DESI-MSI data analysis
  - Transmission electron microscopy
SUPPLEMENTAL INFORMATION

Supplemental information can be found online at https://doi.org/10.1016/j.cell.2022.110453.

ACKNOWLEDGMENTS

This work was conducted with support from the Stanford Cancer Institute (an NCI-designated Comprehensive Cancer Center), George Fisher (Stanford Cancer Institute), NIH awards DK05150 and DK19555 (J.P.A.), and the Child Health Research Institute, Lucile Packard Foundation for Children’s Health, as well as the Stanford CTSI (UL1 TR00186).

AUTHOR CONTRIBUTIONS


DECLARATION OF INTERESTS

The authors declare no competing interests.

Received: July 9, 2021
Revised: November 3, 2021
Accepted: February 7, 2022
Published: March 1, 2022

REFERENCES


# STAR + METHODS

## KEY RESOURCES TABLE

<table>
<thead>
<tr>
<th>RESOURCE or REAGENT</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antibodies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-GFP</td>
<td>Abcam</td>
<td>Cat# ab13970</td>
</tr>
<tr>
<td>Anti-Cytochrome C</td>
<td>Santa Cruz</td>
<td>Cat# sc-15156</td>
</tr>
<tr>
<td>Anti-H3K9me3</td>
<td>Active Motif</td>
<td>Cat# 39062</td>
</tr>
<tr>
<td>Anti-TFAM</td>
<td>GeneTex</td>
<td>Cat# GTX103231</td>
</tr>
<tr>
<td>Anti-HIF1a</td>
<td>Abcam</td>
<td>Cat# ab51608</td>
</tr>
<tr>
<td>Anti-HIF2a</td>
<td>Novus</td>
<td>Cat# N8100-122</td>
</tr>
<tr>
<td>Anti-STAT3</td>
<td>Active Motif</td>
<td>Cat# 39069</td>
</tr>
<tr>
<td>Anti-KW67</td>
<td>Abcam</td>
<td>Cat# ab14667</td>
</tr>
<tr>
<td>Anti-Tyrosine Hydroxylase</td>
<td>Abcam</td>
<td>Cat# ab1212</td>
</tr>
<tr>
<td>Anti-Synaptophysin</td>
<td>Abcam</td>
<td>Cat# ab32127</td>
</tr>
</tbody>
</table>

**Biological samples**

- Human PPSILs and normal Adrenal Gland: Stanford Tumor Bank, n/a
- Mouse RNA-Seq data (NAM, SDHB/NF1, HET/NF1): Sequence Read Archive, PRJNA780868

**Experimental models: Organisms/Strains**

- B6, 129S6-Gli1ROSA26Sor+/+ : The Jackson Lab, 007676
- B6, 129S6-Gli1ROSA26Sor+/+J: The Jackson Lab, 017640
- B6, C5-765D60H223 raftcre/wt+/+Muc2CreERT2: The Jackson Lab, 008601
- B6, 129S6-Gli1ROSA26Sor+/+Muc2CreERT2/J: The Jackson Lab, 003015-JUC
- B6, 129S6-Gli1ROSA26Sor+/+Muc2CreERT2/Rain1: The Jackson Lab, 003086
- SDHIBTP: This paper, n/a

**Oligonucleotides**

- HK2 FWD: GGGGAGCCCTTCGCAGTTTATGTG
- HK2 REV: GAGAACACAAACACGCTTTG
- ND1 FWD: CTAGGCAAGAAACCGCGG
- ND1 REV: CGGGCTGGATATCTCGG
- 16S RNA FWD: GGCGAAGGCCAGGTAAGAC
- 16S RNA REV: TCGTCTGTTCTGGAGGG

**Software and algorithms**

- Velocity 6.3: Perkin Elmer, n/a
- GSEA 4.1.0: Broad Institute/UC San Diego, n/a
- GraphPad Prism v.9.0, n/a
- ClustVis: https://bit.ly/28yhu9v, n/a
- MSReader v1.02: https://msreader.wordpress.ucsf.edu, n/a

## RESOURCE AVAILABILITY

### Lead contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Justin Annes (annes@stanford.edu).

### Materials availability

SDHIBTP mice will be made available on request, but may require payment for shipping/handling costs and a material transfer agreement if there is a potential for commercial application.
Data and code availability
RNA sequencing data has been deposited in NCBI's Sequence Read Archive (SRA) under accession code PRJNA780868 and are publicly available as of the date of publication. This study does not report the development of any new code. Any additional information required to reanalyze the data in this paper will be made available from the lead contact upon request.

EXPERIMENTAL MODELS AND SUBJECT DETAILS

Mice
Th-Cre (#008601), NF1F1 (#17640) and mT/mG (#007576) mice were obtained from The Jackson Labs. The Gulo" mice were obtained from UC Davis Mouse Biology Program. These mice have all been described previously (Muzumdar et al., 2007), (Savitt et al., 2005), (Cao et al., 2007), (Maeda et al., 2000). SDHB" mouse lines were generated from ES cell clone SDHB"1EU/CM1(CM1)(MGE:506535) obtained from EuMMCR and injected into C57BL/6J blastocysts. After breeding of chimeras, pups carrying germinal SDHB" were identified by coat color and tailgenotyping PCR. SDHB"1EU/CM1 animals were bred to FLI1 mice (AXR #009086) to generate SDHB"1EU/CM1. All strains were genotyped using standard PCR methods. Mice were maintained in a mixed 12/12h light/dark cycle under controlled temperature and humidity. Both male and female mice were used except when noted. Gulo' animals were kept in a regular animal facility and were provided ad libitum 3.3% /1 supernatant water with 1% NaCl. All animal experiments were performed in compliance with the Institutional Animal Care and Use Committee and the Stanford University Administrative Panel on Laboratory Animal Care (APLAC). Animals were used at three timepoints: 10 weeks, 5-6 months and 1+ year.

Human samples for DESI-MSI
One healthy adrenal and 9 PPGLs were obtained as either freshly dissected samples or as fresh frozen tissue from the Stanford Tumor Bank (Table S1). Two samples (PGL-5 and -6) overlapped with samples used in Cytochrome C IHC analysis.

Human samples for cytochrome C analysis
Thirty paraffin embedded human PPGL tumor blocks (15 PCCs and 15 PGLs) with known genetic testing results and/or SDHB immunohistochemistry (IHC) were retrieved from the Stanford Tumor Bank. PCC samples included four cluster 1 and eleven non-cluster 1 tumors (Table S2). PGL samples included ten cluster 1 and five non-cluster 1 PGLs (Table S2). PPGLs were classified as cluster 1 (pseudohypoxic) and non-cluster 1 tumors, based on genetic testing results and/or SDHB immunohistochemistry. If SDHB mutation was classified as "benign" or "VUS" while the tumor exhibited "preserved" SDHB by IHC, the tumor was classified as non-cluster 1. Tumors with preserved cytoplasmic SDHB IHC were classified as non-cluster 1 tumors, excluding those tumors with known cluster 1 gene mutation such as VHL or FH. Genetic testing performed in this study cohort ranged from limited analyses of 3 genes for SDHB mutations (SDHB, C, & D) to more comprehensive sequencing analyses of up to 104 genes.

METHOD DETAILS

mT/mG fluorescence imaging and GFP area quantification
Adrenals were fixed for 1-2 hours in 4% paraformaldehyde (PFA) in 0.01 M phosphate-buffered saline (PBS) and rinsed in PBS before equilibration in 30% sucrose in PBS overnight at 4°C. Cryoprotected samples were immersed in O.C.T. compound and frozen at -80°C. OCT blocks were mounted on a cryostat and the cortex was trimmed away. Once the medulla was exposed, every 2nd or 3rd 10μm sections were mounted on charged slides for a total of ~30 sections per gland. Slides were washed in PBS to remove OCT and mounted with Vectashield Antifade plus DAPI. 5-7 sections per gland were imaged on a Leica fluorescent microscope. Images were processed in Volocity 6.3 by hand drawing the medulla outline and then calculating the area within the medulla covered by GFP' cells. The percentage of GFP' medulla area is reported as the average of 5-7 images from each animal. A minimum of 3 animals per genotype were used. Male animals were used for this data set as the female X-chromosome medullae did not show medulla less accurate.

Histopathology and immunohistochemistry
Freshly removed adrenals were fixed in 4% paraformaldehyde overnight at 4°C. transferred to 70% ethanol and then processed for paraffin-embedding at the Stanford Animal Histology Core. For immunohistochemistry, 5μm thick sections were deparaffinized, rehydrated and antigens retrieved in 10mM citric acid at pH 6.0 in a pressure cooker for 10min. Slides were blocked for 1 hour in 5% normal donkey serum plus 0.1% Triton X-100 in PBS. Primary antibodies were diluted in blocking buffer and slides were incubated overnight at 4°C followed by 3 PBS washes and one hour incubation in appropriate fluorophore-conjugated secondary antibodies (Jackson Immunoresearch). Stained sections were mounted in DAPI antifade and imaged using the Leica DM IL LED microscope equipped with a digital Leica DFC425 camera (Wetzlar, Germany). Signal intensities of target antigens were quantified using Volocity 6.3 (PerkinElmer, Waltham, MA, USA). Quantification of the target antigen GFP'/GFP' fluorescence intensity was calculated by creating masks for GFP' medulla area and inverting that mask for GFP' medulla areas. The average pixel intensity of both blue (DAPI) and red (epitope of interest) channels within each mask was measured per image. Images from at least 3 animals per genotype were averaged for each measurement (both genders included).
Human tumor cytochrome C immunostaining and image analysis

Cytochrome C immunostaining was performed using the Leica software. Images were captured using a 2.5X and 10X magnification to identify representative and viable tumor tissue areas. Image capture was done using tiles scan function at 20X and 40X magnification; exposure time was set at 200 milliseconds for all samples. Representative images which include tumoral (T) and non-tumoral (NT) areas were chosen for subsequent image analysis. Image analysis software ( Velocity 6.3) was used for quantification of cytochrome c, comparing its immunofluorescence intensities in tumoral areas versus non-tumoral areas. Tumoral areas were identified by their unique structural arrangements such as Zellballen/nest, trabecular, sheet-like or solid architecture as well as synaptophysin positivity. Tumor capsule, adrenal cortex (n: POC samples), blood vessels wall and/or fibrovascular tissue were used as internal negative controls and designated as non-tumoral areas. Cytochrome c expression were designated as “strong”, “moderate” or “weak” or “absent” if T to NT ratio >2, between 1.8-2, between 1.5-1.8 and <1.5 respectively. This cut-off value was empirically determined based on our experience with biomarker image analysis. Degenerative or necrotic tumor areas (reflected by weak or negative immuno-reactivity of synaptophysin) and areas with extensive hemorrhage (indicated by falsely elevated intensities and bright background signals) were excluded from analysis.

Western blotting

Mouse medulla were surgically removed by manual trimming away of the cortical layer. Both medulla from one mouse were pooled and homogenized in 100ul of RIPA plus protease inhibitors. 10ug of protein were loaded per lane on a 10% SDS-PAGE. Proteins were transferred to nitrocellulose for immunoblotting, blocked in 5% non-fat milk and incubated overnight in the corresponding antibody. After incubation with HRP-conjugated antibodies, bands were visualized on a Bio-Rad ChemDoc Imaging System.

DESI-MSI

DESI-MSI imaging was performed using a lab-built probe constructed of two concentric, fused silica capillaries: an outer sheath gas capillary, 350/250 μm (O.D./I.D.), and an inner solvent capillary of 150/50 μm for the SDHB/NF1 tissue sets and 150/20 μm for the GULO and human tissue sets. A histologically compatible solvent mixture of 1:1 (v/v) dimethyl-formamide/acetoneitrile (Eberlin et al., 2011) was used at a rate of 1 μL/min, and nebulization was aided with 160 psi of nitrogen sheath gas for the SDHB/NF1 tissue sets and 140 psi for the GULO and human tissue sets. A spray voltage of −5 kV was applied to the syringe needle. The probe tip was angled at 56° from the horizontal plane and positioned 6.7 mm above the surface of the slide. Images were acquired using a custom-built moving stage coupled to a high-resolution LTQ Orbitrap XL mass spectrometer (Thermo Fisher) with a pixel size of 115 × 130 μm, 118 × 130 μm, and 181 × 200 μm for the SDHB/NF1, GULO, and human tissues, respectively. The pixel size was determined by the cycle time per scan, the lateral speed of the moving stage, and the vertical step size. The orbitrap was used as the mass analyzer with resolving power set to 60,000. Automatic gain control was turned off, and the maximum ion injection time was set to 100 ms per microscan, corresponding to one scan per pixel, for the SDHB/NF1 tissue sets, and 500 ms per microscan for the GULO and human tissue sets. The capillary temperature was set to 275°C. Spectra were collected over the m/z range 50-1,000. The capillary voltage was set to −65 V, and the tube lens voltage was set to −120 V.

Tissues were mounted in optimal cutting temperature (O.C.T) compound before freezing on dry ice and cryosectioned in 10 μm sections for DESI-MSI. Slides were imaged using a vacuum desiccator prior to imaging. All tissue sets were imaged on the same day to minimize variability, except for the 12+ month glands, which were measured over two sequential days. For the SDHB/NF1 tissue sets, a fluorescent image of the section imaged by DESI-MSI was subsequently taken.

Identification of ion species by MS/MS

Collision-induced dissociation (CID) of a tissue extract was used to accurately identify and assign peaks of interest. The spectra can be shared upon request. For extraction, one whole adrenal gland, approximately 3 mg of tissue, from a No Cre mouse was macerated and then suspended in 200 μL of 1:1 (v/v) methanol:water for 15 minutes with periodic vortexing. The mixture was spun down at 11000 rpm, and the supernatant removed for standard electrospray ionization (ESI). Tandem-MS was performed on the LTQ Orbitrap XL with a lab-built ESI spray constructed of 365/100 μm (O.D./I.D.) fused silica capillary. The spray tip was positioned approximately 8 mm from the inlet; the tissue extract pump rate was 5 μL/min; and the nitrogen sheath gas pressure was 110 psi. The orbitrap was used as the mass analyzer with a resolution of 60,000. The capillary temperature, spray voltage, capillary voltage, and tube lens voltage were the same as described for the DESI-MSI experiments above.

On-tissue fragmentation was performed using the DESI-MSI setup to verify the succinate and ascorbate peaks on a GULO tissue and a human SDHB paraganglioma, as well as norepinephrine on a SDHB/HET tissue. These CID spectra were acquired while the DESI probe scanned the tissue with the same speed and parameters as used for imaging.

Fragmentation patterns were compared to those in standard databases, including Metlin (Scripps Research, La Jolla, CA) (Smith et al., 2009), (Guilas et al., 2018) Lipid Maps (Fathy et al., 2007), and the Human Metabolome Database (HMDB), to make peak assignments. We also compared measured accurate masses with previously published literature values. (Wu et al., 2010, Gu et al., 2018).

DESI-MSI data analysis

Spectra were acquired in Xcalibur 2.5.5 (Thermo Fisher Scientific), with each row of an image comprising a separate .raw file. The .raw files were converted to the .mzML format using MSConvert (Protein Wizard tool) (Kessler et al., 2008), (Chambers et al., 2012) and
then .xml files were compiled into one .imzML image file per sample using imzMLConverter (version 1.3, provided as part of the MSIReader package) (Race et al., 2012). Image files were then visualized in MSIReader version 1.01 (Robichaud et al., 2013), (Bokhart et al., 2016) using the jet color scheme, where red is the most and blue the least intense. All image intensities were scaled as a percentage of total ion current unless otherwise specified. Smoothed images were linearly interpolated. The m/z tolerance was set to ±5 ppm, in accordance with the mass accuracy of the orbitrap mass analyzer.

DESI MSI, as conducted in these experiments, is semi-quantitative. Relative changes in metabolite intensities, normalized as a percentage of total ion current, were used to assess changes over the control. The mean intensity for a metabolite was found by averaging the normalized abundance values for all pixels within a given ROI. Zeros, when present, were included in the mean.

The ROI intensity averages for each metabolite were then exported to GraphPad for further statistical analysis. All comparisons and tests of statistical significance were only made within a tissue set, e.g., 12+ month adrenals, GULO adrenals, or human tissues, to avoid batch effects.

For the SDHb/NF1 tissue sets, the medulla was the ROI, because it was the targeted location of genetic recombination. To guide selection of pixels in the adrenal medulla, fluorescence microscopy images by DESI were overlaid onto the MS image set in MSIReader. Microscopy images were first scaled by the tissue dimensions, and then a series of metabolites and lipids were used to correlate the fluorescent and MS images, including PI(38-4), FA(20-6), succinate, and ascorbate. For metrullia-specific analysis, pixels that were 50% or more within the adrenal medulla, as determined by comparison with the fluorescent overlay, were designated as part of the medulla ROI.

For the GULO and human tissues, the ROI was the entire tissue, where PI(38-4) was used as a guide for the outer tissue border. In a few cases, some water-soluble metabolites leaked slightly from the tissue and may not have been included in the ROI, although they are visible in the DESI-MS images. In these cases, succinate intensities per tissue, and therefore fold-change, may have been even higher than that reported.

**Transmission electron microscopy**

Samples were fixed in Karnovsky’s fixative: 2% Glutaraldehyde (EMS Cat# 16000) and 4% paraformaldehyde (EMS Cat# 15700) in 0.1M Sodium Cacodylate (EMS Cat# 12300) pH 7.4 for 1 h. The fix was replaced with cold aqueous 1% Osmium Tetraoxide (EMS Cat# 19100) and were then allowed to warm to Room Temperature (RT) for 2 hrs rotating in a hood, washed 3x with ultrapure water, then en bloc stained in 1% Uranyl Acetate at RT 2 hrs while rotating. Samples were then dehydrated in a series of ethanol washes for 30 minutes each at RT beginning at 50%, 70% ETOH then moved to 40% overnight. They were placed in cold 95% ETOH and allowed to warm to RT, changed to 100% 2x then Propylene Oxide (PO) for 15 min. Samples are infiltrated with EMBed-812 resin (EM Cat# 14125) mixed 1:2, 1:1, and 2:1 with PO for 2 hrs each with leaving samples in 2:1 resin to PO overnight rotating at RT in the hood. The samples are then placed into EMBed-812 for 2 to 4 hours then placed into molds with labels and fresh resin, oriented and placed into 65°C even overnight.

Sections were taken around 80nm using an UC7 (Leica, Wetzlar, Germany) picked up on formvar/Carbon coated 100 mesh Cu grids, stained for 40s in 3.5% Uranyl Acetate in 50% Acetone followed by staining in Sato’s Lead Citrate for 2 minutes. Observed in the JEOL JEM-1400 120KV. Images were taken using a Gatan OneView 4k x 4k digital camera.

**RNA-seq**

Adrenals used for RNA-seq came from 16-18M old animals. For tumors samples (SDHb/NF1 and HET/NF1 animals), pheochromocytomas were removed, weighted and immersed in ice-cold PBS while cortex was manually trimmed away. For normal aged medulla controls, cortex was manually removed before processing. Normal medulla tissue from 2 animals (4 total medullae) were pooled in order to get enough tissue for experimentation. Tissue was transferred to RNAlater and stored at −80°C until processing. Total RNA and DNA were purified from tissue using the Qiagen AllPrep kit according to the manufacturer’s instructions. RNA quality was assessed by bioanalyzer. Library preps were carried out using an Illumina kit with PolyA selection. Sequencing was done on Illumina HiSeq (2 x 150bp) to a minimum depth of 50M reads per sample. Clustering was performed in Clustvis (https://bitt.cs.ut. ee/clustvis/) and gene set enrichment analysis was carried out with GSEA 4.1.0 (Broad Institute).

**Mitochondrial DNA copy number assay**

Real-time qPCR on DNA extracted from mouse SDHb/NF1 and HET/NF1 tumors and aged-matched NAM was used to measure mitochondrial DNA copy number. Hexokinase 2 primers were used to measure nuclear DNA and ND1 and 16S RNA primers were used to quantify mitochondrial DNA. 100ng of DNA was input into each qPCR assay with Sybr Green and 1μM primers.

**Assessment of glucose homeostasis**

Glucose physiology experiments were performed on female SDHb/HET and No Cre 12+ old animals. Blood glucose levels were obtained with glucose meter (Contour next EZ, Parsippany, NJ, USA). For glucose tolerance test, mice were fasted for 16 h and blood glucose levels were measured at indicated times following intraperitoneal injection of 2 g glucose (Sigma) per kg of body weight. For insulin tolerance test, mice were fasted for 6 h and blood glucose levels were measured at indicated times following intraperitoneal injection of 1U Insulin (Humalog) per kg of body weight. Homeostasis model assessment-insulin resistance (HOMA-IR) was calculated to assess changes in insulin resistance: Insulin (pmol/L) × glucose (mmol/L)/22.5. HOMA β-cell function as a percentage
(HOMA-B%) was calculated to assess steady state β-cell function: insulin (pmol/L) × 25/g glucose (mmol/L) – 3.5. Both were calculated using fasting values.

QUANTIFICATION AND STATISTICAL ANALYSIS

Volocity was used for quantification of signal intensity for all immunohistochemistry images and all mt/mg images. GraphPad Prism software was used for all statistical analysis. For statistical analysis of mouse and human data, the mean ± SEM of independent subjects was used. For analysis of statistical significance, either unpaired t-tests, one-way ANOVA or two-way ANOVA was used. Statistical details (p-values) of experiments can be found in the figure legends.
Supplemental information

SDHB knockout and succinate accumulation are insufficient for tumorigenesis but dual SDHB/NF1 loss yields SDHx-like pheochromocytomas

Neali Armstrong, Claire M. Storey, Sarah E. Noll, Katherine Margulis, Myat Han Soe, Haixia Xu, Benjamin Yeh, Lauren Fishbein, Electron Kebebew, Brooke E. Howitt, Richard N. Zare, Julien Sage, and Justin P. Annes
Figure S1. Ultrastructure of HET and SDHB chromaffin cells and GFP co-staining with TFAM, 5hmc and Hif1α. Related to Figure 2.
Figure S2. Animal and adrenal gland weights and catecholamine levels for 18-28 week old animals. Related to Figure 4. A) Average male adrenal gland weights for all 5 genotypes. B) Average male animal weights for all 5 genotypes. C) Average catecholamine levels in the medulla measured by DESI-MSI for 4 genotypes. Data are presented as mean ± SD and analyzed using unpaired t-test. ** p<0.01.
**Figure S3. SDHB/HET animals have adult onset non-diabetic obesity.** Related to Figure 4. A) Combined male and female animal weights at sacrifice (>12+ months old) for 4 genotypes. B) H&E images from control and SDHB/HET pancreas show increased islet size. C) Insulin Tolerance and D) Glucose Tolerance and E) Fasting Serum Insulin levels for SDHB/HET and No Cre controls. F) HOMA-IR and HOMA-B. (n = 4-8). Data are presented as mean ± SD and analyzed using an unpaired t-test. **p<0.01.
Figure S4. Analysis of control adrenal glands and mouse tumors. Related to Figure 5. (A) Adrenal tissue from HET/HET mice reveal non-neoplastic medulla (M) and cortex (C). The HET/NF1 image depicts the prototypical appearance of adrenal pheochromocytoma with nested clusters of epithelioid tumor cells containing granular eosinophilic cytoplasm surrounded by a rich vascular network. Some SDHB/NF1 tumors demonstrated similar morphology but with a slightly more trabecular growth pattern in areas. Other SDHB/NF1 tumors demonstrated more abundant granular amphophilic cytoplasm and nuclear enlargement imparting a ganglion-like morphology to the tumor cells. Note the nests of tumor cells wrapped in delicate vasculature typical of pheochromocytoma. (B) Quantification of Cytochrome C (CytC) staining in human PPGL samples as a ratio of Tumor Cell intensity to non-Tumor Cell intensity. DAPI is used as internal control. Data are presented as mean ± SD and analyzed using an unpaired t-test. **** p<0.0001. (C) Principle component analysis of mouse RNA-seq data. (D) Normalized counts for SDHx subunit validates the heterozygous and homozygous knockout of SDHB in HET/NF1 and SDHB/NF1 tumors, respectively. (E) Gene set enrichment analysis using the Hallmark pathways for human germline SDHx and NF1 pheochromocytoma from the TCGA database.
Figure S5. Loss of ascorbate after 6 weeks of depletion in 10 week old female GULO<sup>−/−</sup> adrenals. 
Related to Figure 7. PI(38:4) is shown as a positive control. All DESI-MS images were normalized as a % TIC.
<table>
<thead>
<tr>
<th>Tumor</th>
<th>Site</th>
<th>Size (cm)</th>
<th>Age</th>
<th>Sex</th>
<th>Pathogenic mutation</th>
<th>SDHB IHC</th>
<th>Succinate peak</th>
<th>Succinate Fold Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal Adrenal</td>
<td>Adrenal</td>
<td>11</td>
<td>41</td>
<td>F</td>
<td>NA</td>
<td></td>
<td>0.033</td>
<td>1</td>
</tr>
<tr>
<td>PGL-5</td>
<td>Abdominal</td>
<td>13</td>
<td>65</td>
<td>F</td>
<td>SDHB c.418G&gt;T (p.V140F)</td>
<td>Loss</td>
<td>3.501</td>
<td>106.1</td>
</tr>
<tr>
<td>PGL-32</td>
<td>Abdominal</td>
<td>3</td>
<td>40</td>
<td>M</td>
<td>SDHD c.112C&gt;T (p.R38*)</td>
<td>Loss</td>
<td>4.468</td>
<td>135.4</td>
</tr>
<tr>
<td>PGL-30</td>
<td>Para-aortic</td>
<td>15.8</td>
<td>42</td>
<td>F</td>
<td>SDHB c.136C&gt;T (p.R46*)</td>
<td>Loss</td>
<td>1.068</td>
<td>32.4</td>
</tr>
<tr>
<td>PGL-6</td>
<td>Chest</td>
<td>5</td>
<td>35</td>
<td>F</td>
<td>None*</td>
<td>Intact</td>
<td>2.462</td>
<td>74.6</td>
</tr>
<tr>
<td>PCC-17</td>
<td>R Adrenal</td>
<td>2</td>
<td>47</td>
<td>M</td>
<td>None</td>
<td>Intact</td>
<td>0.017</td>
<td>0.5</td>
</tr>
</tbody>
</table>

Table S1: Characteristics of human PPGLs in DESI-MSI Experiment. Related to Figure 5F. PGL: paragangliomas; PCC: pheochromocytoma; R: right; L: left; M: male; F: female; SDHB IHC: succinate dehydrogenase B immunohistochemistry; NA: not available/applicable;

None* FH VUS (FH c.2T>G) with robust FH IHC and negative/weak 2-SC IHC. Patient is suspected Carney Triad with multiple tumors including GIST. Genetic testing (Ambry Genetics, PGLNext, 2015) included sequence, indel and deletion/duplication analysis for MAX, NF1, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, TMEM127 and VHL.
Table S2: Human PPGL Samples For Cytochrome C Study

<table>
<thead>
<tr>
<th>Tumor</th>
<th>Site</th>
<th>Size (cm)</th>
<th>Age</th>
<th>Sex</th>
<th>Pathogenic mutation</th>
<th>SDHB IHC</th>
<th>T-CytC</th>
</tr>
</thead>
<tbody>
<tr>
<td>PCC-1</td>
<td>Bilateral</td>
<td>3 (R), 1.7 (L)</td>
<td>41</td>
<td>M</td>
<td>SDHD c.112 C&gt;T</td>
<td>Loss</td>
<td>Strong</td>
</tr>
<tr>
<td>2</td>
<td>Right</td>
<td>2.9</td>
<td>54</td>
<td>M</td>
<td>SDHB c.141G&gt;A</td>
<td>Loss</td>
<td>Moderate</td>
</tr>
<tr>
<td>3</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>VHL c.524A&gt;G</td>
<td>Not Done</td>
<td>Weak</td>
</tr>
<tr>
<td>4</td>
<td>Right</td>
<td>3.4</td>
<td>60</td>
<td>M</td>
<td>VHL</td>
<td>Preserved</td>
<td>Strong</td>
</tr>
<tr>
<td>5</td>
<td>Right</td>
<td>3</td>
<td>23</td>
<td>F</td>
<td>SDHB p.568S*</td>
<td>Preserved</td>
<td>Strong</td>
</tr>
<tr>
<td>6</td>
<td>Right</td>
<td>2.5</td>
<td>61</td>
<td>F</td>
<td>TMEM127 c.570del</td>
<td>Preserved</td>
<td>Weak</td>
</tr>
<tr>
<td>7</td>
<td>Bilateral</td>
<td>4 (R), 5.2 (L)</td>
<td>44</td>
<td>F</td>
<td>None</td>
<td>Preserved</td>
<td>Weak</td>
</tr>
<tr>
<td>8</td>
<td>Left</td>
<td>9</td>
<td>57</td>
<td>F</td>
<td>None</td>
<td>Preserved</td>
<td>Weak</td>
</tr>
<tr>
<td>9</td>
<td>Right</td>
<td>3.8</td>
<td>51</td>
<td>M</td>
<td>None**</td>
<td>Preserved</td>
<td>Weak</td>
</tr>
<tr>
<td>10</td>
<td>Left</td>
<td>6</td>
<td>61</td>
<td>M</td>
<td>None**</td>
<td>Preserved</td>
<td>Weak</td>
</tr>
<tr>
<td>11</td>
<td>Left</td>
<td>5.5</td>
<td>33</td>
<td>M</td>
<td>RAD51D c.694C&gt;T</td>
<td>Preserved</td>
<td>Moderate</td>
</tr>
<tr>
<td>12</td>
<td>Right</td>
<td>4</td>
<td>58</td>
<td>M</td>
<td>None</td>
<td>Preserved</td>
<td>Weak</td>
</tr>
<tr>
<td>13</td>
<td>Right</td>
<td>4</td>
<td>35</td>
<td>F</td>
<td>RET c.1901G&gt;T</td>
<td>Preserved</td>
<td>Weak</td>
</tr>
<tr>
<td>14</td>
<td>Right #</td>
<td>1.2</td>
<td>5</td>
<td>F</td>
<td>None</td>
<td>Preserved</td>
<td>Weak</td>
</tr>
<tr>
<td>15</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NF1</td>
<td>Not done</td>
<td>Weak</td>
</tr>
<tr>
<td>PGL-1</td>
<td>Retro-peritoneal</td>
<td>11</td>
<td>41</td>
<td>M</td>
<td>SDHB c.600G&gt;A</td>
<td>Loss</td>
<td>Strong</td>
</tr>
<tr>
<td>2</td>
<td>Rectum</td>
<td>8.5</td>
<td>40</td>
<td>F</td>
<td>SDHB c.201-2A&gt;C</td>
<td>Loss</td>
<td>Strong</td>
</tr>
<tr>
<td>3</td>
<td>Para-aortic</td>
<td>7</td>
<td>20</td>
<td>M</td>
<td>SDHA2 c.320G&gt;A</td>
<td>Loss</td>
<td>Strong</td>
</tr>
<tr>
<td>4</td>
<td>Para-aortic</td>
<td>5</td>
<td>32</td>
<td>F</td>
<td>SDHB c.79C&gt;T</td>
<td>Loss</td>
<td>Weak</td>
</tr>
<tr>
<td>5</td>
<td>Peritoneal</td>
<td>10.5</td>
<td>65</td>
<td>F</td>
<td>SDHB c.418G&gt;T</td>
<td>Loss</td>
<td>Moderate</td>
</tr>
<tr>
<td>6</td>
<td>Retro-peritoneal</td>
<td>3</td>
<td>36</td>
<td>F</td>
<td>None***</td>
<td>Equivocal</td>
<td>Strong</td>
</tr>
<tr>
<td>7</td>
<td>R Glomus Jugulare</td>
<td>6</td>
<td>22</td>
<td>F</td>
<td>SDHA In7-del#*</td>
<td>Loss</td>
<td>Strong</td>
</tr>
<tr>
<td>8</td>
<td>L Carotid body</td>
<td>2</td>
<td>32</td>
<td>F</td>
<td>SDHD c.147dupA</td>
<td>Loss</td>
<td>Strong</td>
</tr>
<tr>
<td>9</td>
<td>L Carotid body</td>
<td>1.8</td>
<td>43</td>
<td>F</td>
<td>NA</td>
<td>Loss</td>
<td>Strong</td>
</tr>
<tr>
<td>10</td>
<td>L Carotid body</td>
<td>4</td>
<td>39</td>
<td>M</td>
<td>SDHB c.136C&gt;T</td>
<td>Loss</td>
<td>Strong</td>
</tr>
<tr>
<td>11</td>
<td>R lung</td>
<td>1.9</td>
<td>56</td>
<td>F</td>
<td>None</td>
<td>Equivocal</td>
<td>Scant</td>
</tr>
<tr>
<td>12</td>
<td>L Carotid body</td>
<td>6</td>
<td>32</td>
<td>M</td>
<td>NA</td>
<td>Preserved</td>
<td>Weak</td>
</tr>
<tr>
<td>13</td>
<td>L middle ear</td>
<td>1.1</td>
<td>62</td>
<td>F</td>
<td>NA</td>
<td>Preserved</td>
<td>Moderate</td>
</tr>
<tr>
<td>14</td>
<td>Bladder</td>
<td>4.1</td>
<td>60</td>
<td>F</td>
<td>NA</td>
<td>Preserved</td>
<td>Moderate</td>
</tr>
<tr>
<td>15</td>
<td>L Glomus Jugulare</td>
<td>5.8</td>
<td>22</td>
<td>M</td>
<td>None</td>
<td>Not done</td>
<td>Strong</td>
</tr>
</tbody>
</table>
Table S2: Characteristics of human PPGLs used in Cytochrome C study. Related to Figure 5.
PCC: pheochromocytoma; PGL: paragangliomas; R: right; L: left; M: male; F: female; MN: metanephrine; NM: normetanephrine CgA: chromogranin A; SDHB IHC: succinate dehydrogenase B immunohistochemistry; T-Cyta: cytochrome c expression in tumor cells; NA: not available/applicable; (n) = folds elevated above upper limit of normal value.
* SDHD mutation was reported as a benign variant.
** POLD1 VUS
*** FH VUS (FH c.2T>G) with robust FH IHC and negative/weak 2-SC IHC. Patient is suspected Carney Triad with multiple tumors including GIST. Genetic testing (Ambr Genetics, PGLNext, 2015) included sequence, indel and deletion/duplication analysis for MAX, NF1, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, TMEM127 and VHL.
# Right composite PCC and neuroblastoma
#* patient also had BRCA 2 c.4712-4713del besides the mentioned SDHA mutation.